<div id="readability-page-1"><p>Barclays analyst Etzer Darout maintained a Buy rating on Legend Biotech today and set a price target of $80.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Darout is a 5-star analyst with an average return of <span>26.4%</span> and a 56.04% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Legend Biotech, and Jazz Pharmaceuticals.</p> <p>In addition to Barclays, Legend Biotech also received a Buy from H.C. Wainwright’s Mitchell Kapoor in a report issued yesterday. However, on the same day, TD Cowen maintained a Hold rating on Legend Biotech (NASDAQ: LEGN).</p></div>

LEGN

IBBQ

LABU

<p>Barclays analyst Etzer Darout has reaffirmed a Buy rating on Legend Biotech (LEGN) with a price target of $80.00. Darout, a 5-star analyst with a 26.4% average return, also covers other healthcare stocks. Additionally, H.C. Wainwright's Mitchell Kapoor issued a Buy rating for Legend Biotech, while TD Cowen maintained a Hold rating on the same stock.</p>

Tip Ranks

Legend Biotech

SPDR S&P Biotech

VG Health

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Barclays

Incyte

Jazz Pharma

Toronto Dominion Bank

Barclays Reaffirms Their Buy Rating on Legend Biotech (LEGN)